EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


LinkedIn facebook twitter youtube
News archive
Recent news

 

Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound that is approved the United States Food and Drug Administration (FDA) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. During the American Society of Hematology (ASH) Annual Meeting, new results of this myeloma drug were presented. Dr Cristina Gasparetto, Duke Cancer Institute, North Corolina, USA, explains for Myeloma Patients Europe (MPE) the main results of selinexor.

 

  

 







Recent news

» Join MPE's webinar on doctor and patients’ perspectives on myeloma CAR-T

» Study shows the importance of vaccination for myeloma patients

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy